Atovaquone for treatment of COVID-19: A prospective randomized, double-blind, placebo-controlled clinical trial

Background: An in silico screen was performed to identify FDA approved drugs that inhibit SARS-CoV-2 main protease (M(pro)), followed by in vitro viral replication assays, and in vivo pharmacokinetic studies in mice. These studies identified atovaquone as a promising candidate for inhibiting viral r...

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, Mamta K., De Lemos, James A., McGuire, Darren K., Ayers, Colby., Eitson, Jennifer L., Sanchez, Claudia L., Kamel, Dena, Meisner, Jessica A., Thomas, Emilia V., Hegde, Anita A., Mocherla, Satish, Strebe, Joslyn K., Li, Xilong, Williams, Noelle S., Xing, Chao, Ahmed, Mahmoud S., Wang, Ping, Sadek, Hesham A., Schoggins, John W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561237/
https://www.ncbi.nlm.nih.gov/pubmed/36249792
http://dx.doi.org/10.3389/fphar.2022.1020123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561237/
https://www.ncbi.nlm.nih.gov/pubmed/36249792
http://dx.doi.org/10.3389/fphar.2022.1020123

Ejemplares similares